Monthly Archives: September 2020

PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials

HERZLIYA, ISRAEL / ACCESSWIRE / September 29, 2020 / PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that following the closing of its initial public offering, it has commenced preparations for the launch of its pivotal Phase 3 clinical trials of PRF-110 for the treatment of post-operative pain. Upon completion of the Phase 3 studies, if successful, the Company plans to apply for a New Drug Approval for the management of post-operative pain.

Based on extensive toxicology and pharmacokinetic studies, as well as positive Phase 2 results, the FDA has granted the Company an IND for PRF-110 and approved the initiation of Phase 3 trials for the treatment of post-operative pain. Unlike many drug trials that take months to years to complete, which are complex and whose endpoints are difficult to interpret, the planned trials are expected to last for a brief number of days with a one-month follow-up, with primary endpoints based on measurement on the familiar scale of 1 (no pain) to 10 (worst imaginable pain).

PRF-110 is a viscous, waterless, clear oil-based solution that is instilled (deposited) directly into the surgical wound to provide localized and extended post-operative analgesia. Its physical characteristics and composition are key to it being well-tolerated. The solution allows for ease of administration by the surgeon.

Key attributes of PRF-100 include:

PRF-110 is highly viscous and thus stays in place when administered into a surgical wound bed covering the inner surface of the surgical wound.
PRF-110 remains within the surgical site when the wound is closed, without toxicity or proinflammatory effects.
PRF-110 is easy to administer and its use is consistent with current surgical practice.
PRF-110, being a solution, is highly uniform, resulting in consistent and sustained/extended release of the analgesic.
Ropivacaine, the active drug used in PRF-110, is a safe and well-characterized local anesthetic.
The components that make up the remainder of the PRF-110 formulation are classified as GRAS (Generally Regarded As Safe) by the FDA.

Dr. Ehud Geller, the Chairman of the Board of the Company commented, "Following the successful completion of our initial public offering for gross proceeds of $20 million, we have commenced preparations for the initiation of our pivotal Phase 3 clinical trials. The current market in post-operative pain treatment is approximately $12 billion, which is expected to grow to over $45 billion by the end of 2026 (Persistence Market Research, 2018). PRF-110 was created to prolong analgesia at the surgical site, thus facilitating early post-operative ambulation, speeding recovery and reducing time in hospital. We are extremely excited to take the next step on this journey to provide relief to patients for post-operative pain and hopefully contribute to the reduction in the frequency of opiate use, thereby lessening the risk of opiate abuse disorder."

About PainReform

PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company's proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates.

Notice Regarding Forward-Looking Statements

This press release contains certain forward-looking statements, including statements with regard to PainReform's proposed clinical trials. Words such as "expects," "anticipates" and "intends" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the clinical trials discussed above will be successfully completed. Completion of the proposed clinical trials are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, failure of the clinical trials, and the risk factors and other matters set forth in the Company's recent prospectus included in the registration statement, in the form last filed with the SEC. PainReform undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contact:

Crescendo Communications, LLC
Tel: 212-671-1021
Email: prfx@crescendo-ir.com

SOURCE: PainReform Ltd.

ReleaseID: 608241

Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECH Technology in Delivering Antiviral Drugs

Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 Applications

KELOWNA, BC / ACCESSWIRE / September 29, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today provides an update on a previously announced antiviral research initiative and introduces a new research project with potential COVID-19 applications.

On March 19 2020, Lexaria announced that it planned to conduct a pilot human pharmacokinetic exploratory study in healthy volunteers of antiviral drugs that have previously been studied against other coronavirus strains, comparing Lexaria's DehydraTECHTM formulations to controls without Lexaria's technology.

The ethics board approval required as a first step in this pilot study has now been received, conditional on further government regulatory approval also being granted. Lexaria will now begin the process of pursuing the necessary steps to file for approval from federal regulators.

In parallel with this, Lexaria is also announcing the launch of a separate rodent antiviral study to evaluate pharmacokinetic benefits from the use of DehydraTECH in the delivery of representative drugs from two classes of antiviral drugs heavily under investigation against COVID-19 today. The drugs to be used have already been processed with DehydraTECH and sent to the testing facility. Dosing of the rodents has already begun and study results are expected in December 2020.

"We are excited at this progress towards our pilot human study using our patented DehydraTECH platform in the delivery of antiviral drugs, and are continuing the process towards regulatory approval so we can advance this important study," said Chris Bunka, CEO of Lexaria. "Additionally, we are pleased to have started an animal study using DehydraTECH on certain potential COVID-19 drugs under investigation. Not only will this study help to determine whether DehydraTECH is capable of delivering higher proportionate doses of the antiviral drugs than generic versions of the drugs, but the outcomes should also be beneficial in gaining regulatory approval for the planned human study."

As background, many antiviral drugs are fat soluble and known to present significant bioavailability challenges in successfully reaching the human bloodstream in therapeutic quantities when administered in oral form. Lexaria's expertise in the enhanced oral delivery of fat-soluble drugs could offer significant benefits to antiviral drug administration that potentially could remove the need for costly and uncomfortable injected treatments frequently used today.

Additional research may include expanded pharmacokinetic and pharmacodynamic screening, including studies in appropriate coronavirus animal models with the antiviral drugs Lexaria is currently investigating and/or others from their classes for efficacy evaluation. If Lexaria's technology is proven to increase delivery effectiveness of antiviral drugs, the Company will make its technology available to researchers throughout the world looking to maximize the effectiveness of their own drug investigations.

Enhancement of delivery properties of antiviral drugs is consistent with Lexaria's strategy as a drug delivery platform innovator for multiple applications. The Company believes DehydraTECH may prove useful in the fight against COVID-19 and other viruses that are expected to be investigated in the future. Chris Bunka, CEO, is responsible for the accuracy of this news. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

About Lexaria

Lexaria Bioscience Corp.'s (OTCQX: LXRP, CSE: LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 – 2 hours to 10 – 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.

INVESTOR CONTACT:

ir@lexariabioscience.com
Phone: 866-221-3341

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out the antiviral research initiatives, receive regulatory approvals or experience positive effects from any antiviral research or study.. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing any active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Lexaria Bioscience Corp.

ReleaseID: 608131

Woodstock Hospital Receives ROI Award

For their implementation of PaperVision® Enterprise

GREENWOOD VILLAGE, CO / ACCESSWIRE / September 29, 2020 / Nucleus Research has selected Woodstock Hospital as an 18th annual Technology ROI Award winner for its implementation of PaperVision Enterprise and PaperFlowTM. This award recognizes companies whose skillful deployment of IT solutions has produced a positive, bottom-line financial return on investment (ROI).

The Nucleus ROI Awards recognize the top 10 technology projects of the year based on the overall value delivered by the project. Nucleus Research analysts performed an independent ROI assessment calculating the actual business benefits and ROI achieved by each project; winners were chosen based strictly on the ROI recognized from their implementation.

Companies who receive the Technology ROI Award demonstrate the link between IT strategy and business goals. For Woodstock Hospital, this meant finding a way to access paper patient records from care provided prior to 2005, when they adopted an Electronic Health Records (EHR) application. To optimize patient care, they wanted medical staff to be able to instantly view both newer EHRs and older patient files side-by-side electronically. The implementation of PaperVision Enterprise, which allows Woodstock Hospital to securely store and access all their medical records electronically, generates a $437,500 average annual benefit while helping care providers quickly make life-saving decisions. The final analysis shows 258% ROI with full project payback in just three months.

"After implementing an EHR application, Woodstock Hospital was not getting the full benefit they had hoped for. They purchased PaperFlow to help convert older paper-based patient records to electronic files and integrated PaperVision Enterprise with the EHR to simplify records search. They improved staff efficiency, boosted control of sensitive patient information, and reduced the costs of managing their healthcare records while supporting outstanding patient care in their Emergency Department. The overall result was 258% ROI and almost half a million dollars saved annually."

Barbara Peck
Analyst, Nucleus Research

"In today's environment, we want front-line healthcare workers to have every tool they need to provide the best patient care possible. Digitech Systems is pleased to congratulate Woodstock Hospital," said HK Bain, CEO of Digitech Systems. "It's rewarding to see the ability of PaperVision Enterprise to work alongside their EHR to securely present patient records electronically leading to improved efficiency and real savings, especially with the extra security required in the world of healthcare."

This innovative implementation was provided by Polar Imaging, a Digitech Systems reseller based in London, Ontario Canada. Polar Imaging has been a Digitech Systems reseller since 2004, and they are a member of the 2020 Circle of Excellence. "Resellers play an important role by matching organizational needs and goals with product capabilities to maximize ROI," explained Bain. "Polar Imaging demonstrates the essential role of a reseller in their work with Woodstock Hospital. Congratulations and thank you to Greg and Steve Todd and the entire team at Polar Imaging."

See the Woodstock Hospital case study and video, and learn more about PaperVision Enterprise and PaperFlow by visiting our website.

About Digitech Systems, LLC

Digitech Systems, LLC enables businesses of any size to more effectively and securely manage, retrieve and store corporate information of any kind using either PaperVision Enterprise content management (ECM) software or the world's most trusted cloud-based ECM service, ImageSilo. By significantly reducing the cost, Digitech Systems has moved ECM from a luxury convenience to an essential element for every well-managed business.

Digitech Systems continues to raise the standard of excellence in the ECM sector, as evidenced by the numerous awards they have received including multiple Nucleus Research ROI Awards. In addition, Buyer's Lab has repeatedly chosen PaperVision Capture as the best data capture and workflow solution and PaperVision® Enterprise as the most outstanding ECM software in the marketplace. To learn more about the company's software and services that deliver any document, anywhere, anytime, visit www.digitechsystems.com.

Contact:

Elizabeth Edwards
+17205294850
edwards@volumepr.com

SOURCE: Digitech Systems

ReleaseID: 608268

Best Friends Pet Hotels Announces Exclusive Nutrition Partnership with Freely Starting October 1

Freely will be the Exclusive Nutrition Partner for both dogs and cats staying and playing  at all 31 Best Friends Pet Hotel centers nationwide

NORWALK, CT / ACCESSWIRE / September 29, 2020 / As cooler weather descends and holiday preparations are underway, pet parents are starting to think about holiday plans, including pet boarding accommodations and day care arrangements. For busy families, Best Friends Pet Hotels provides peace of mind with a new exclusive partnership offering Freely limited ingredient recipes as the new in-house food starting October 1st.

According to Darryl Sampson, Best Friends Pet Hotel VP/Operations, "We are proud to partner with Freely, a brand that shares our commitment to being a trusted resource for today's pet parents as well an excellent complement to our quality facilities and luxury pet suites. Freely's unique natural, limited ingredient foods and personalized, free nutrition services is one more way we're demonstrating our dedication to providing exceptional care for our happy canine and feline guests, and peace of mind for pet parents."

Through this partnership with Freely, Best Friends Pet Hotels nationwide will be making the switch exclusively to Freely recipes. Dogs staying and playing with Best Friends Pet Hotels will enjoy Whole Grain Lamb kibble or a Whole Grain Turkey Puppy kibble while cats boarding with Best Friends will enjoy Grain-Free with Rabbit kibble. Select wet recipes will also be available. Kibble samples are available for free at local Best Friends Pet Hotels while supplies last.

"High quality food and thoughtfully balanced nutrition are important to the overall health of every pet," said Freely Veterinarian, Dr. Sara Gilbert. "Freely provides peace of mind for pet parents not only by delivering complete and balanced nutrition in every bowl but as a great resource to coach and advise them and the staff at Best Friends. When a pet's home-away-from-home care is equally committed to rigorous play and purposely chosen foods, it shows their dedication to the families they serve."

Best Friends will also be selling Freely's Beneficial Broths (for dogs, Tranquility Blend, Gut Health Blend, Skin & Coat Blend, and Tranquility Blend; for cats, Tranquility Blend) in the lobby and available for curbside pickup. Customers of Best Friends will also enjoy an exclusive discount code for online purchases at freelypet.com.

Freely was created to simplify pet food for pet parents who are largely overwhelmed and confused by today's market. They offer a unique service and product model that makes it easier for pet parents to select and buy their pet's food. Freely puts small animal nutrition experts within easy reach through the Freely Nutrition Center and offers an innovative assortment of limited ingredient recipes perfect for nourishing pets.

About Freely: Freely Pet, LLC was started in 2020 by a group of passionate pet parents committed to making pet food easier to understand and buy. Freely products are available online at freelypet.com, Chewy.com, and Amazon.com, and at select local neighborhood pet retail stores across the US. The company is driven by its purpose of enabling pet parents to nourish their pets with confidence and ease. All Freely products are Limited Ingredient Diet recipes made in the USA from the finest ingredients from around the world. Freely offers a selection of premium dry and wet foods as well as functional bone broth toppers for both dogs and cats, in a range of protein options from vegetarian and flexitarian to meat and fish. Freely is privately held and headquartered in Brentwood, Missouri, and can be visited at freelypet.com and followed on Instagram, Facebook, and Twitter at @freelypet.

About Best Friends Pet Hotel: Founded in 1995 and currently employee-owned, Best Friends

Pet Hotel has enjoyed "leader of the pack" status for nearly 25 years. With 31 locations, including Walt Disney World, we strive to provide customers with the absolute best pet care in a convenient and friendly atmosphere where safety, comfort, and fun are at the core of what we do. In addition to high quality grooming, Best Friends Pet Hotels offers boarding, Doggy Day Camp, and training services with full transparency, great communication with pet parents, the

latest advances in safety, and a caring staff that loves your pet as much as they love their own. Many hotels offer outside and inside play areas designed with the latest advances in materials and safety. Learn more at http://www.bestfriendspetcare.com.

For more information, visit www.bestfriendspetcare.com and find the location near you for questions about your pet's food during boarding or day care, or to order ahead for easy curbside pickup for retail sales.

###

Julie Dennehy, APR
Dennehy Public Relations
julie@dennehypr.com, 508-479-9848

SOURCE: Best Friends Pet Hotel

ReleaseID: 608077

Marizyme, Inc. Completes Acquisition of Somahlution, Inc. and Raises $7.0 Million in Private Placement

JUPITER, FL / ACCESSWIRE / September 29, 2020 / Marizyme, Inc. ("Marizyme" or the "Company"), a publicly traded (OTCQB:MRZM) company focused on acquiring late-stage drug and medical device assets announced today that it has completed the acquisition of all or substantially all of the Somahlution, Inc. and Somahlution, LLC assets, including their DuraGraft® intellectual property, Somaceutica intellectual property and derivative works. DuraGraft is a CE-marked and patented product that protects vascular grafts against ischemic injury and is the only product registered and indicated for graft protection and preservation during bypass and other vascular surgeries including Coronary Artery Bypass Graft (CABG) and Peripheral Bypass surgery. Marizyme has issued 10 million shares of restricted common stock to the Somahlution shareholders and a warrant to purchase 3 million shares of restricted common stock at an exercise price of $5 per share.

In addition, Marizyme also raised $7.0 million in gross proceeds in a private placement where Univest Securities, LLC acted as the exclusive placement agent. Marizyme plans to use the proceeds to expand sales of DuraGraft in Europe and to begin to seek US FDA approval in the United States.

As part of the transaction Dr. Satish Chandra will be joining Marizyme as President and COO and Dr. Catherine Pachuk will be joining as Chief Science Officer.

Mr. James Sapirstein, Marizyme, Executive Chairman, commented, "We are excited to complete this transaction and most importantly bring on the seasoned technical leadership of the Somahlution team. In addition, we are grateful to Univest Securities and our new investors for the trust they are placing in us to deliver strong shareholder value for Marizyme."

Somahlution's platform technology has enabled the development of a robust product pipeline with the potential to address unmet medical needs and reduce disease burden not only in vascular grafting indications but also indications involving tissue and fat grafting and organ transplant. DuraGraft protects graft tissue from harvesting through anastomosis and is used as a treatment to maintain the structural and functional integrity of free vascular grafts. The use of DuraGraft is associated with reductions of post-CABG complications associated with graft disease and failure: Myocardial Infarction, Repeat Revascularization and other Major Adverse Cardiac Events.

Dr. Satish Chandran, Marizyme, President and COO, added, "We are enthusiastic about being a key element of Marizyme's strategy. DuraGraft has undergone extensive and rigorous clinical testing and has been cleared for use throughout the EU and several other countries around the world."

About Marizyme, Inc.

Marizyme, Inc. is a development-stage company dedicated to the commercialization of innovative therapies that address the urgent unmet needs relating to higher mortality and costs in the acute care space. Specifically, Marizyme will focus its efforts on expanding the applications for its technologies to dental care, wound healing, thrombosis and other tissue preserving uses. For more information, visit www.marizyme.com or www.somahlution.com.

About Univest Securities, LLC.

Registered with FINRA since 1994, Univest Securities, LLC provides a wide variety of financial services to its institutional and retail clients globally including brokerage and execution services, sales and trading, market making, investment banking and advisory, wealth management. It strives to provide clients with value-add service and focuses on building long-term relationship with its clients. For more information, please visit: www.univest.us.

Forward-Looking Statements

This press release may contain certain forward-looking statements, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company's control, affect the Company's operations, performance, business strategy and results and there can be no assurances that the Company's actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, including those risks set forth in the Company's risk factor disclosure in the reports that we file with the U.S. Securities and Exchange Commission, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Relations Contact

Eric Kash
eric@marizyme.com

SOURCE: Marizyme, Inc.

ReleaseID: 608260

Forestry Machinery Market to Exceed US$ 6 Bn Towards 2030 end; Market Sales Interrupted due to COVID-19 Outbreak, Opines Fact.MR

Key forestry machinery market players are focusing on launching new products to extend their customer base and attain a competitive superiority over other players.

ROCKVILLE, MD / ACCESSWIRE / September 29, 2020 / The forestry machinery market is poised to experience moderate growth at a CAGR of around 5% over the assessment period, 2020-2030. The growing focus of players on designing machinery for higher manufacturing applications, extreme terrain conditions, and demanding operations, will augur well for the forestry machinery market growth.

"The COVID-19 impact will have long-term significance on the forestry machinery market growth. Even after the relaxation of lockdown measure, the demand will remain muted by 2020 end, due to uncertain economic conditions. However, developing nations of APAC will exhibit a positive outlook, together with a move towards the mechanized mode of operations, fostering the forestry machinery demand in the coming years," says the Fact.MR report.

Request a report sample to gain comprehensive market insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=3732

Forestry Machinery Market – Key Takeaways

By type, the air heater category is slated to witness mounting demand due to progressions in the automobile sector.
Based on vehicle technology, the BEV segment will record a stellar CAGR of 25% throughout the assessment period, to be estimated at US$ 3.5 Billion towards 2030-end.
Based on the vehicle, the demand for Forestry Machinery for passenger cars will remain dominant by holding over 90% of the market share.
By maximum heat capacity, the 4-7 kW capacity segment will record a CAGR of 24% throughout 2020-2030.
China will remain dominant in the global market owing to the high growth in the automobile industry.

Forestry Machinery Market – Driving Factors

Technological progressions in the electrical sector will facilitate several development prospects for the market
Escalating demand for customized products according to application perquisites by several OEMs will boost the market demand in the approaching years.
New public-private partnerships are designed to hasten the development of the electric vehicle sector, which also multiplies the market size.
Progressions in the automotive sector and the development of several concepts such as electric cars, connected cars, and smart cars will complement market growth.

Forestry Machinery Market – Constraints

Maintenance cost competitiveness in the worldwide market is a major restraint to market expansion.
Steady maintenance prerequisites to ascertain smooth operations, compliance with several regulations while developing novel products, and high investment costs are poised to limit the market growth.

Anticipated Market Impact by COVID-19 Outbreak

The COVID-19 outbreak has caused grave repercussions for the forest-based industry, consecutively, affecting the forestry machinery sales. The outbreak has ensued in a forest management operations slowdown, together with interrupted supply chains and a drop in wood outlets, a majority of the forest products are exported and imported in the log form. These challenges will have major implications for the worldwide forestry machinery market.

Explore the Forestry Machinery market comprising of 80 figures and 76 data tables, along with the table of contents. You can find a detailed market segmentation on https://www.factmr.com/report/3732/forestry-machinery-market

Competition Landscape

Key companies identified in the forestry machinery market are Tigercat International Inc., Komatsu Ltd., Deere & Co., Caterpillar, Inc. Barko Hydraulics L.L.C., AGCO Corporation, Ponsse Oyj, Kubota Corporation, and Rottne Industri AB.

More on the Report

The FACT.MR's market research report provides in-depth insights into the Forestry Machinery market. The market is scrutinized based on machine (forwarders, skidders, swing machines, harvesters, bunchers, loaders, and other forestry machinery), across five major regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA)).

Explore Wide-ranging Coverage of FACT.MR's Industrial Goods Landscape

Forestry Excavators Market: Find insights on the forestry excavators market with analysis of segments, statistics, influencers, market players, and business strategies adopted over a 10-year forecast period.

Trace Moisture Generator Market: FACT.MR's report on the trace moisture generator market offers insights on the market during 2020-2030, including restraints, revenue sources, market leaders, and market strategies.

Gear Measuring Machines Market: Read an analysis of the gear measuring machines market with insights on growth factors, opportunities, restraints, regional market forecast, regulatory policies, and strengths of market leaders.

About Fact.MR

Fact.MR is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Fact.MR is headquartered in Dublin, and has offices in Dubai. FACT.MR's latest market research reports industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

Contact:

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1643/forestry-machinery-market-trends

SOURCE: Fact.MR

ReleaseID: 608251

Advertisers Can Now Include OTT Advertising in Multi-Touch Attribution Models

OTT effectiveness and contribution to the customer journey now measurable using new capabilities from LeadsRx

PORTLAND, OR / ACCESSWIRE / September 29, 2020 / Today, LeadsRx announced new capabilities for over-the-top (OTT) advertisers within the suite of capabilities available in its impartial marketing attribution platform. These capabilities allow advertisers to incorporate OTT ad analytics within multi-touch attribution models, which is the primary way marketers assess ad performance and make spend optimizations. Previously, OTT attribution could only be evaluated in isolation, potentially leading to wrong or even damaging marketing decisions.

With consumers cutting the cord at an accelerating rate – with 50 million more expected to do just that by 2021, LeadsRx Attribution™ gives marketers a single software platform to compare the effectiveness of OTT advertising to other marketing channels while showing OTT as another marketing touchpoint within the customer journey that includes podcast ads, TV, AM/FM radio, Google and Facebook ads, and other forms of digital advertising.

Marketers benefit from LeadsRx attribution analysis because they can use it to measure the return on ad spend (ROAS) and give more accurate attribution of OTT advertising, allocating proper credit to the other touchpoints often impacted by OTT ads like organic and paid search. Previously, these incremental channels were often receiving undue credit for their influence on conversions because OTT advertisements were driving people to engage with those channels. With impartial multi-touch attribution, OTT ads can receive an accurate share of conversions because the marketing data is being evaluated on one universal platform – not across several point solutions.

LeadsRx OTT Attribution is available immediately and is seamlessly integrated into the existing multi-touch attribution capabilities available within LeadsRx, for no additional charge.

LeadsRx Unlocks Knowledge of ACR Data

LeadsRx has unlocked the insights in automatic content recognition (ACR) technologies and cross-screen metrics to incorporate ACR data and OTT ads in the LeadsRx attribution equation, giving marketers the ability to incorporate OTT ad analytics within their multi-touch attribution models.

As an impression-based broadcast medium, OTT advertising can be personalized to connect with consumers in ways traditional TV advertising cannot. OTT advertising has the added tracking ability of ACR data to report when ads were shown – and LeadsRx uses that ACR data to connect individual customer journeys across devices and marketing channels. This shift provides advertisers who use attribution the ability to attribute touchpoints and conversions down to the IP address and device which was exposed to the advertisement.

Prior to LeadsRx OTT attribution, organic and paid search results were often given credit for web visits and digital touchpoints simply because the OTT ad was tracked by a point solution – in a data silo separate from the rest of the multi-touch marketing landscape.

The LeadsRx Open Attribution API ingests data from third-party ACR providers to provide details on when and what ads were shown to each household. LeadsRx Attribution processes this data and determines if people from that household visited the advertiser's website or took other digital action. The LeadsRx Universal Conversion Tracking Pixel™, found on the advertiser's website, captures these digital interactions and stiches together complete customer journeys – including OTT ads.

With impartial, multi-touch data, advertisers and marketing agencies leverage the attribution reports within LeadsRx to unlock the insights they need to not only optimize their OTT ads, but to optimize how those ads perform in conjunction with all their other marketing programs.

LeadsRx Attribution eliminates human intervention, typographical errors, and results in faster more accurate insights. With the addition of OTT support, LeadsRx Attribution now covers an industry leading number of marketing channels:

Digital: Facebook, Google, and all other digital ad networks
Broadcast: All mediums like AM/FM radio, satellite radio, TV, OTT, podcasts, and direct mail
Impressions: Tracking for channels like display ads and email marketing
Mobile: Track in app events and conversions
Offline: The Open Attribution API allows for marketers to pass touchpoint and conversion data from custom applications, third party integrations and data layers

"The way media is consumed is rapidly evolving, with cord-cutting and new technologies dramatically transforming consumer viewing habits requiring marketers to be more strategic with advertising in order to connect and build trust for brands with millennials," says AJ Brown, CEO and co-founder of LeadsRx. "LeadsRx continues to lead the industry by constantly expanding our marketing attribution offerings to give marketers and advertisers all the tools they need to optimize ad spend."

About LeadsRx

A fast innovator and a marketer's choice for 4,000-plus global and local brands, LeadsRx is an unrivaled multi-touch attribution SaaS platform. Powered by a unique Universal Conversion Tracking Pixel™, LeadsRx provides an impartial view of customer journeys, giving each advertising touchpoint proper weight and credit including broadcast media. Founded by marketers, LeadsRx enables companies of any size to elevate marketing performance in a framework that is easily understood delivering sustainable return on ad spend (ROAS). To learn more about how LeadsRx can support you in marketing transformation visit LeadsRx.com. Connect with LeadsRx on Twitter, LinkedIn and Facebook.

For more information

Jeff Fishburn
Fishburn PR for LeadsRx
jeff@fishburnpr.com

SOURCE: LeadsRx

ReleaseID: 607905

American Kidney Fund Expands Rare Disease Initiatives with Education and Awareness Campaign About Fabry Disease

Campaign explores Fabry disease as a cause of unexplained chronic kidney disease and empowers people diagnosed with Fabry to educate family members about genetic link

ROCKVILLE, MD / ACCESSWIRE / September 29, 2020 / Recognizing the unmet needs of the Fabry disease community, the American Kidney Fund (AKF) today announced an education and awareness campaign to increase visibility of Fabry disease and encourage chronic kidney disease (CKD) patients who do not know the underlying cause of their kidney disease to get tested for Fabry disease. The campaign was made possible through a partnership with Sanofi Genzyme, which has been committed to supporting the rare disease community for more than 35 years.

Fabry disease, a rare genetic disorder diagnosed in approximately 1 in 40,000 people, is caused by a mutation of the GLA gene, which results in decreased production of an enzyme that breaks down a fatty substance called globotriaosylceramide, or GL-3. This leads to a buildup of GL-3 in cells throughout the body. Over time, Fabry disease can lead to CKD and end-stage renal disease (ESRD, or kidney failure). It can also cause damage to the heart and brain. Symptoms and severity of Fabry disease can vary from person to person, even within families, and the disease has no cure.

Since Fabry disease is complex and the symptoms are non-uniform, the disease often goes unrecognized or misdiagnosed until patients have life-threatening complications such as stroke, heart attack or kidney failure. With an early diagnosis, doctors can intervene earlier and possibly help delay serious complications.

"For patients with a rare condition like Fabry disease, the road to a diagnosis and proper treatment can be long and painful," said LaVarne A. Burton, AKF president and CEO. "This partnership with Sanofi Genzyme allows us to expand our educational materials on Fabry disease, increase awareness of the condition, and empower patients with practical guides they can use when discussing their health with their doctors or with their families."

AKF's new Fabry disease campaign uses digital media, including social media, to reach and engage patients. Visitors to AKF's website will find a set of resources tailored to their health status at KidneyFund.org/fabry.

CKD patients without a Fabry disease diagnosis

Resources for these patients focus on the importance of understanding the root cause of a CKD diagnosis for patients who have not been given a reason for their kidney disease:

Educational information about getting tested for Fabry disease, so people with CKD with an unknown cause can learn more about Fabry disease.
A doctor conversation guide to help kidney patients determine the questions they should consider asking their nephrologist about Fabry disease and whether it could be the underlying cause of their unexplained CKD.

While these resources are for men and women alike, AKF will conduct special outreach to women, who were once assumed only to be carriers of Fabry disease. Both men and women are at risk for Fabry disease and can experience its symptoms, though the symptoms may differ between gender, causing mis- or underdiagnosis of Fabry disease in females.

CKD patients who have been diagnosed with Fabry disease

Resources for these CKD patients focus on the importance of those who have already been diagnosed with Fabry disease to consider talking about the disease with their families. Included in these resources is a guide to help patients understand the genetic link in Fabry disease, because on average, five other family members may be affected as well. These resources will provide educational information to Fabry disease patients to explain to their family members the importance of getting tested for Fabry disease to detect it early.

"Sanofi Genzyme has been a trusted partner with the Fabry community by providing support and education for people living with Fabry disease, their caregivers and physicians," said Sarah Ryan, head of Fabry and MPS I, and Renal Marketing at Sanofi Genzyme. "We are excited to partner with AKF to launch this educational campaign to increase the awareness of Fabry disease within the CKD community. We hope these educational materials will help those who are living with Fabry, as well as those who might be at risk for Fabry."

About Us

The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation's leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease-from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation's top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar.

For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn.

Contacts

Elissa Blattman
Associate Director of Communications
eblattman@kidneyfund.org
11921 Rockville Pike, Suite 300, Rockville, MD 20852
Work: 301-984-6644 
KidneyFund.org

Links

KidneyFund.org/fabry

SOURCE: American Kidney Fund

ReleaseID: 608135

Core Assets Corp. Initiates Permitting for Drilling and Plans Airborne Geophysical Survey at the Blue Cu-Au Property, Atlin, British Columbia

VANCOUVER, BC / ACCESSWIRE / September 29, 2020 / Core Assets Corp., ("Core Assets" or the "Company") (CSE:CC)(Frankfurt:5RJ)(WKN:A2QCCU) is pleased to announce that it has applied for exploration permitting for diamond drilling and has begun planning for the initiation of a 1,100 line kilometer geophysical survey at its 100% wholly owned Blue Property (the "property") located in the Atlin Mining District of British Columbia, Canada.

Highlights

Core Assets has added 10 new diamond drill holes to a historically permitted diamond drilling program of 8 holes that the vendor had on the property, for a total of 18, targeting newly identified chargeability targets outlined by the 2019 IP survey and compilation of historic electro magnetic survey on the western part of the property.

The execution of a property wide magnetic and radiometric geophysical survey will add new layers to delineate secondary and tertiary structures associated with mineralization and alteration found around the Llewelyn Fault Zone (LFZ). The LFZ is a major regional fault in the Atlin area, running from the Yukon, south 140 km's to the British Columbia-Alaska border.

The Blue Property hosts a historical diamond drill hole* that assayed 173.2 meters of 0.27% Cu from surface, 1.60% Cu from 173.2-179.2 meters,1.40% Cu from 186.2-194.0 meters and is open in all directions.

The Silver Lime Property hosts massive sulfide at surface with historical channel samples* of 3.3 g/t Au, 2,641 g/t Ag, 0.15% Cu, 2.5% Pb and 3.32% Zn, 2.56% Sb over 2.2 meters and has never been drilled to date.

The geophysical survey is planned to start in late October and drilling is estimated to begin in Spring 2021.

CEO David Hodge comments, "The execution of a state-of-the-art geophysical survey will help us upgrade our precision for drill placement. We believe that it is important to understand the alteration associated with deep seated secondary and tertiary structures that are fed by the Llewelyn Fault Zone. The Llewelyn Fault Zone exhibits characteristics of other prolific mining and exploration camps to the south, and we believe that it has the potential to be associated with a district scale plumbing system on our property. This survey will be yet another very important steppingstone in adding new geological layers that will help our highly experienced technical team lead us to discovery."

Core Assets believes that the south Atlin Lake area and the LFZ, which runs approximately 140 km from the Yukon border to the Juneau Ice Sheet in the United States, has been neglected since the last major exploration campaigns in the 1970's. The LFZ runs directly through the property and is thought to be the main transport corridor for the mobilization and concentration of high-grade metals seen at surface on the property. The last 50 years have seen incremental advancements in the understanding of porphyry, skarn and carbonate replacement type deposits both globally and in the Golden Triangle area, with new discoveries being made annually. The sum of this knowledge is now coming together in discrete and effective exploration models that the Company believes could drive a major discovery. Core Assets intends to leverage this shift in understanding and become one of the most extensive explorers in the northernmost extent of the Golden Triangle saga.

The Core Assets team has significant experience and knowledge in the Atlin Mining District. They have studied the entirety of the south Atlin Lake, where there is an opportunity for world class discoveries and mine development.

About the Blue and Silver Lime projects

Blue Property

In 2018, the Company sent a geological team to the Blue property for preliminary surface sampling. The field crew observed three areas of skarn exposure with massive and disseminated visible sulfide along the western side of the Llewellyn Regional Fault Zone. 28 grab samples were taken and sent to the laboratory for geochemical analysis and returned values of up to 1.57 g/t gold, 46.5 g/t silver and 8.46% copper.

In 2019, Core Assets contracted Aurora Geosciences Ltd. for the execution of an induced polarization geophysical survey over the areas of high priority mineralization which confirmed and highlighted areas of elevated chargeability response over visible skarns and identified multiple chargeable porphyry style targets.

Later in 2019, Nick Rodway, P. Geo. (Director of Core Assets Corp.) and Matthew Carter (Qualified Person of Dahrouge Geological Consulting Ltd.) visited the property to reanalyze some of the high priority areas identified by the 2018 and 2019 programs. The program successfully confirmed elevated gold, silver and copper values.

The amalgamation of Core Asset's newly obtained geological information, and the historical exploration data, including the 1973 exploration program undertaken by Rio Plata Silver Mines Ltd., where a single diamond drill hole assayed 173.2 meters of 0.27% Cu from surface, 1.60% Cu from 173.2-179.2 meters and 1.40% Cu from 186.2-194.0 meters will serve as a bases to complete further structural analysis for placement of drill holes. This could potentially lead to a new porphyry style discovery in British Columbia.

Silver Lime Property

The Silver Lime Property is located just 10 km west of the Blue Property (now contiguous) and was originally acquired by Core Assets as a secondary project. Through rigorous desktop geological study by Core Assets' technical team, it has been deemed that the same exploration model revolving around fluid mobilization of the Llewellyn Fault Zone also applies to the west.

Historically, the Silver Lime Property consisted of two significant mineral occurrences known as the Falcon and Jackie showings. The Falcon showing was discovered by Carmac Resources in 1990 and consists of two northwest trending quartz veins. Mineralization comprises galena, sphalerite, pyrite, chalcopyrite, arsenopyrite and stibnite. The vein system is exposed for 25 meters and the strike extensions are covered by talus. Individual veins are up to 1.2 meters wide.

To the northwest, a quartz-feldspar porphyry breccia contains smaller quartz veins with semi-massive arsenopyrite and stibnite. A 2.20 meter wide sample* of the vein system assayed 3.3 g/t gold, 2,641 g/t silver, 0.15% copper, 2.5% lead and 3.32% zinc, 5.0% arsenic and 2.56% antimony (Assessment Report 21162).

In 2018, Zimtu Capital Corp., as part of a helicopter reconnaissance program, prospected the property taking 8 samples. The results confirmed the program that Carmac did in 1990, returning values reaching 1.16 g/t gold, 913 g/t silver, 12.45% zinc and >20.0% lead.

The Silver Lime Property potentially fits a carbonate replacement deposit model (CRD). Massive sulphide pods occur in limestone and biotite-muscovite-sericite schists generally near the contacts between the units. Large zones of limonite alteration, cut by alaskite and hornblende porphyry dikes, usually surround the pods. The lenses appear to be widest near the dikes. Several faults follow the general direction of the dikes, suggesting structural control on the mineralization. Sulphides comprise galena, sphalerite chalcopyrite, pyrrhotite and pyrite. The pods are up to 30 meters long and 6 meters wide. The smaller pods host sphalerite and galena mineralization and the larger pods vary mineralogically along length. Galena, quartz and calcite dominate the northwest changing to pyrrhotite, chalcopyrite and pyrite in the centre and border areas (Minfile 104M 031).

NI 43-101 Disclosure

Nicholas Rodway, P.Geo, is a Director of the company, shareholder and qualified person as defined by National Instrument 43-101. Mr. Rodway supervised the preparation of the technical information in this news release.

*Historical numbers are provided as an indication that mineralization is present, and is relied on by the Company as encouraging further exploration and assessment of the properties

About Core Assets Corp.

Core Assets Corp. is a Canadian mineral exploration company focused on the acquisition and development of mineral projects in BC, Canada. The company currently holds the Blue and Silver Lime Properties, which cumulatively cover a land area of 14,814.86 Ha (148.15 km²). Both projects lay within the Atlin Mining District, which is a well-known gold camp. The Atlin Mining District has been the focus of Core Assets exploration efforts since 2018, with increased exploration activities forecasted in the area moving into 2021.

Neither the Canadian Securites Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

On Behalf of the Board of Directors
CORE ASSETS CORP.

"David Hodge"
David Hodge
President & Director
Tel: 604.681.1568

FORWARD LOOKING STATEMENTS

Statements in this document which are not purely historical are forward-looking statements, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include that we will get permits to drill 18 targets; that the geophysical survey is planned to start in late October and drilling is estimated to begin in Spring 2021; and that there may be a commercially viable gold or other mineral deposit on our claims. It is important to note that the Company's actual business outcomes and exploration results could differ materially from those in such forward-looking statements. Risks and uncertainties include that permits may not be granted timely or at all; the mineral claims may prove to be unworthy of further expenditure; there may not be an economic mineral resource; methods we thought would be effective may not prove to be in practice or on our claims; economic, competitive, governmental, environmental and technological factors may affect the Company's operations, markets, products and prices; our specific plans and timing of them may change; we may not have access to or be able to develop any minerals because of cost factors, type of terrain, or availability of equipment and technology; and we may also not raise sufficient funds to carry out our plans. Additional risk factors are discussed in the section entitled "Risk Factors" in the Company's Management Discussion and Analysis for its recently completed fiscal period, which is available under Company's SEDAR profile at www.sedar.com. Except as required by law, we will not update these forward looking statement risk factors.

SOURCE: Core Assets Corp.

ReleaseID: 608078

NV Gold Announces Phase I Drill Program at Its Sandy Gold Project in Nevada

VANCOUVER, BC / ACCESSWIRE / September 29, 2020 / NV Gold Corporation (TSXV:NVX)(OTC PINK:NVGLF) ("NV Gold" or the "Company") is pleased to announce it has received necessary drill approvals for its 100% owned Sandy Gold Project ("Sandy") located within the Walker Lane, Lyon County, Nevada, USA. NV Gold's first drill program at Sandy encompasses up to 1,500 m in up to 10 drill holes.

A property-wide geophysical program was recently completed consisting of 198 line-kms of electromagnetic (resistivity and conductivity), magnetic, and radiometric surveys. Raw data is currently being analyzed by senior geophysicists from Goldspot Discoveries Corp. and will assist in delineating high priority drill targets testing this low-sulphidation epithermal gold system.

"We look forward to completing our first drill program at the Sandy Gold Project, which last saw drilling in the early 1990s. We are currently finalizing our drill program that is expected to commence in October 2020," commented Peter A. Ball, President and CEO of NV Gold. "At the same time we are preparing our drill at the Sandy Gold Project, we have recently submitted our drill permit for our 100% owned Slumber Gold Project in Humboldt County, Nevada, which was leased in 2019. We also continue to advance the optioned Exodus Gold Project in BC, Canada, where we can earn up to an 85% interest. This is shaping up to be a very exciting and busy second half of 2020 at NV Gold, with potentially three drill programs to be undertaken."

About the Sandy Gold Project

20 unpatented lode claims encompassing approximately 400 acres acquired for minimal staking costs in 2019 utilizing NV Gold's internal geological database.

Strategically within a highly prospective low sulfidation epithermal gold district located in Lyon County, Nevada, USA.

Staked prior to and now surrounded by the Hercules Gold Project claim block controlled by Eclipse Gold Mining (TSXV: EGLD). Eclipse Gold Mining has raised approximately $20 million to explore and advance its Hercules Project.

Originally explored in 1993-1994 through work including geologic mapping, rock-chip and soil sampling, and drilling. Refer to the Company's press release September 5, 2019 for additional information on historical data.

About NV Gold Corporation

NV Gold (TSXV: NVX, US: NVGLF) is a well-financed junior exploration company based in Vancouver, British Columbia that is focused on delivering value through mineral discoveries in North America, leveraging its highly experienced in-house technical knowledge, and identifying and drilling 2-3 priority projects per year. NV Gold controls multiple drill-ready projects in Nevada, and has entered into an Option Agreement on the high-grade Exodus Gold Project in British Columbia, Canada.

On behalf of the Board of Directors,

Peter A. Ball
President & CEO

For further information, visit the Company's website at www.nvgoldcorp.com or contact:

Peter A. Ball, President & CEO
Phone: 1-888-363-9883
Email: peter@nvgoldcorp.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This news release includes certain forward-looking statements or information. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the Company's planned exploration activities, including executing a drill program at the Sandy, Slumber and Exodus Gold Projects in the Fall of 2020, are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's plans or expectations include regulatory issues, market prices, availability of capital and financing, general economic, market or business conditions, timeliness of government or regulatory approvals and other risks detailed herein and from time to time in the filings made by the Company with securities regulators. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.

SOURCE: NV Gold Corporation

ReleaseID: 608173